A number of firms have modified their ratings and price targets on shares of Hill-Rom Holdings (NYSE: HRC) recently:
- 8/6/2017 - Hill-Rom Holdings was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
- 8/2/2017 - Hill-Rom Holdings was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Hill-Rom exited the third quarter on a mixed note with earnings beating the Zacks Consensus Estimate and revenues missing the same. Moreover, decrease in Patient Support Systems revenues was disappointing. Also, a decline in reported gross margin was dampening. Foreign exchange also remains a headwind. Also, lowered full year guidance suggests dull prospects ahead. On a positive note, Hill-Rom saw a solid year-over-year increase in revenues on strong international growth. Hill-Rom currently aims to gain traction in the untapped international market on successful execution. The company is focusing on product innovation through research and development. Also, its launches slated for the fourth quarter are pumping up investors’ confidence. With regard to this, the commercial launch of its Centrella Med-Surg platform is worth a mention.”
- 7/31/2017 - Hill-Rom Holdings was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
- 7/30/2017 - Hill-Rom Holdings had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $84.00 price target on the stock.
- 7/28/2017 - Hill-Rom Holdings had its price target lowered by analysts at Needham & Company LLC from $95.00 to $93.00. They now have a “buy” rating on the stock.
- 7/28/2017 - Hill-Rom Holdings was given a new $86.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
- 7/24/2017 - Hill-Rom Holdings was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
- 7/11/2017 - Hill-Rom Holdings was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the last three months, Hill-Rom is trading above the broader Medical Product industry. Management is currently looking to gain traction in the untapped international market with its efficient international team and organizational realignment. The company also continues to grow on its strategy of product expansion and diversification with recent launch of its surgical beds. We are also looking forward to the company's plan to divest its non-profitable Volker business to focus more on its core arms. Geographically, over the recent past, Hill-Rom consistently posted strong growth in the U.S. and also delivered a solid gross margin. Management’s outlook for 2017 also raises optimism. However, the company has faced difficulties in the Asia-Pacific region of late. Also, with more than 30% sales generating outside, Hill-Rom faces hitch related to adverse currency fluctuations. The highly competitive market is a major concern.”
- 6/30/2017 - Hill-Rom Holdings had its price target raised by analysts at Morgan Stanley from $85.00 to $90.00. They now have an “overweight” rating on the stock.
- 6/29/2017 - Hill-Rom Holdings is now covered by analysts at Cantor Fitzgerald. They set a “neutral” rating and a $86.00 price target on the stock.
- 6/29/2017 - Hill-Rom Holdings is now covered by analysts at Needham & Company LLC. They set a “buy” rating and a $95.00 price target on the stock. They wrote, “We are initiating coverage of HRC with a Buy rating. Recent acquisitions have diversified HRC’s business and should drive stronger margin expansion and faster EPS growth. Additionally, new products should drive higher organic revenue growth. And while large (>$1B) acquisitions are probably off the table for now, we see potential for additional tuck-in deals over the next 12-18 months.””
- 6/21/2017 - Hill-Rom Holdings was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $90.00 price target on the stock. According to Zacks, “Over the last three months, Hill-Rom is trading above the broader Medical Product industry. Management is currently looking to gain traction in the untapped international market with its efficient international team and organizational realignment. The company also continues to grow on its strategy of product expansion and diversification with recent launch of its surgical beds. Notably, the company demonstrated balanced growth across all three segments in its last reported fiscal second quarter. Geographically, over the recent past, Hill-Rom consistently posted strong growth in the U.S. and also delivered a solid gross margin. Management’s outlook for 2017 also raises optimism. However, the company has faced difficulties in the Asia-Pacific region of late. Also, with more than 30% sales generating outside, Hill-Rom faces hitch related to adverse currency fluctuations. The highly competitive market is a major concern.”
- 6/15/2017 - Hill-Rom Holdings was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the last three months, Hill-Rom is trading above the broader Medical Product industry. Management is currently looking to gain traction in the untapped international market with its efficient international team and organizational realignment. The company also continues to grow on its strategy of product expansion and diversification with recent launch of its surgical beds. Notably, the company demonstrated balanced growth across all three segments in its last reported fiscal second quarter. Geographically, over the recent past, Hill-Rom consistently posted strong growth in the U.S. and also delivered a solid gross margin. Management’s outlook for 2017 also raises optimism. However, the company has faced difficulties in the Asia-Pacific region of late. Also, with more than 30% sales generating outside, Hill-Rom faces hitch related to adverse currency fluctuations. The highly competitive market is a major concern.”
- 6/12/2017 - Hill-Rom Holdings was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $88.00 price target on the stock. According to Zacks, “Over the last three months, Hill-Rom is trading above the broader Medical Product industry. Management is currently looking to gain traction in the untapped international market with its efficient international team and organizational realignment. The company also continues to grow on its strategy of product expansion and diversification with recent launch of its surgical beds. Notably, the company demonstrated balanced growth across all three segments in its last reported fiscal second quarter. Geographically, over the recent past, Hill-Rom consistently posted strong growth in the U.S. and also delivered a solid gross margin. Management’s outlook for 2017 also raises optimism. However, the company has faced difficulties in the Asia-Pacific region of late. Also, with more than 30% sales generating outside, Hill-Rom faces hitch related to adverse currency fluctuations. The highly competitive market is a major concern.”
Hill-Rom Holdings Inc (NYSE HRC) traded down 0.85% during trading on Wednesday, hitting $74.88. 189,012 shares of the company traded hands. Hill-Rom Holdings Inc has a 12-month low of $50.50 and a 12-month high of $84.65. The stock has a 50-day moving average price of $80.26 and a 200-day moving average price of $72.21. The firm has a market capitalization of $4.93 billion, a P/E ratio of 43.64 and a beta of 1.22.
Hill-Rom Holdings (NYSE:HRC) last announced its quarterly earnings results on Friday, July 28th. The medical technology company reported $0.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.90 by $0.01. Hill-Rom Holdings had a return on equity of 19.99% and a net margin of 4.27%. The business had revenue of $689.10 million during the quarter, compared to the consensus estimate of $695.50 million. During the same quarter in the prior year, the company posted $0.81 earnings per share. Hill-Rom Holdings’s revenue was up 5.1% compared to the same quarter last year. Equities analysts expect that Hill-Rom Holdings Inc will post $3.82 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 15th will be issued a dividend of $0.18 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.72 annualized dividend and a yield of 0.95%. Hill-Rom Holdings’s dividend payout ratio (DPR) is currently 41.62%.
In related news, SVP Paul Sherwood Johnson sold 2,078 shares of the company’s stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $72.30, for a total transaction of $150,239.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Andreas G. Frank sold 10,660 shares of the company’s stock in a transaction on Tuesday, June 6th. The stock was sold at an average price of $78.62, for a total value of $838,089.20. Following the sale, the senior vice president now owns 28,988 shares of the company’s stock, valued at approximately $2,279,036.56. The disclosure for this sale can be found here. Corporate insiders own 2.20% of the company’s stock.
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.
